MYC and lymphoma: As a proof of concept that TAK-659 inhibits LMP2A/MYC lymphoma development and to corroborate our tumor cell transfer data, we treated a limited number of MYC (16- to 24-week-old) and LMP2A/MYC (6- to 10-week-old) transgenic mice before they developed tumors.